ryansroberts · July 2, 2014 14:07
diff --git a/README.md b/README.md
diff --git a/current.csv b/current.csv
diff --git a/datapackage.json b/datapackage.json
 {
  "name": "Questions",
  "state": "active",
  "created": "2014-07-02T14:07:20.742Z",
  "sources": [
    {
      "web": "https://raw.githubusercontent.com/ryansroberts/RDFProvider/master/Source%20Content/Guideline&Evidence/Questions.csv"
    }
  ],
  "profiles": {
    "dataexplorer": "0.9"
  },
  "scripts": [
    {
      "id": "main.js",
      "path": "main.js"
    }
  ],
  "views": [
    {
      "id": "grid",
      "label": "Grid",
      "type": "SlickGrid",
      "state": {
        "gridOptions": {
          "editable": true,
          "enabledAddRow": true,
          "enabledDelRow": true,
          "enableReOrderRow": true,
          "autoEdit": false,
          "enableCellNavigation": true
        }
      },
      "queryState": {
        "size": 155,
        "from": 0,
        "q": "",
        "facets": {},
        "filters": []
      }
    },
    {
      "id": "graph",
      "label": "Graph",
      "type": "Graph",
      "queryState": {
        "size": 155,
        "from": 0,
        "q": "",
        "facets": {},
        "filters": []
      }
    },
    {
      "id": "map",
      "label": "Map",
      "type": "Map",
      "queryState": {
        "size": 155,
        "from": 0,
        "q": "",
        "facets": {},
        "filters": []
      }
    }
  ],
  "id": "dataexplorer-398030",
  "resources": [
    {
      "backend": "csv",
      "id": "Questions",
      "path": "current.csv",
      "schema": {
        "fields": [
          {
            "id": "Question GUID",
            "label": "Question GUID",
            "type": "string",
            "format": null,
            "is_derived": false
          },
          {
            "id": "Question",
            "label": "Question",
            "type": "string",
            "format": null,
            "is_derived": false
          }
        ]
      }
    },
    {
      "backend": "csv",
      "id": "Questions-original",
      "path": "original.csv",
      "schema": {
        "fields": [
          {
            "id": "Question GUID",
            "label": "Question GUID",
            "type": "string",
            "format": null,
            "is_derived": false
          },
          {
            "id": "Question",
            "label": "Question",
            "type": "string",
            "format": null,
            "is_derived": false
          }
        ]
      }
    }
  ]
 }
diff --git a/main.js b/main.js
 loadDataset("current", function (error, dataset) {
  // error will be null unless there is an error
  // dataset is a Recline memory store (http://reclinejs.com//docs/src/backend.memory.html).
  console.log(dataset);
 });
diff --git a/original.csv b/original.csv
	Question GUID	Question
	CG15AdultQ1	What is the working clinical definition for Type 1 Diabetes?
	CG15AdultQ2	What is the current burden and trend in burden of Type 1 diabetes in England and Wales?
	CG15AdultQ3	What symptoms are suggestive of a diagnosis of Type 1 diabetes?
	CG15AdultQ4	Which diagnostic tests can confirm diagnosis in a person with suspected Type 1 diabetes?
	CG15AdultQ5	What is the evidence on optimal structures of care, which enable healthcare professionals to give assistance, education and advice to adults with Type 1 diabetes?
	CG15AdultQ6	What support groups help adults with Type 1 diabetes and their families to cope with diabetes?
	CG15AdultQ7	What are the optimal methods of delivering education to adults with Type 1 diabetes?
	CG15AdultQ8	In adults with Type 1 diabetes, what are the optimal methods to improve concordance with self-management?
	CG15AdultQ9	What is the optimum form of self-monitoring of glucose control in adults with Type 1 diabetes?
	CG15AdultQ10	What is the optimum regimen of self-monitoring of glucose control in adults with stable Type 1 diabetes?
	CG15AdultQ11	What dietary advice should be given to adults with Type 1 diabetes to maintain optimal metabolic control?
	CG15AdultQ14	What advice about exercise participation should be given to adults with Type 1 diabetes to maintain optimal blood glucose control?
	CG15AdultQ20	What recommendations can be made for the special needs of members of minority ethnic communities with diabetes?
	CG15AdultQ21	What precautions and lifestyle changes do adults living with Type 1 diabetes need to make to maintain metabolic control?
	CG15AdultQ22	What is an acceptable level of blood glucose control in adults with Type 1 diabetes for the avoidance of complications?
	CG15AdultQ23	What are the optimal methods of managing glucose control in inpatients with stable Type 1 diabetes?
	CG15AdultQ25	What is the optimum method of clinically monitoring blood glucose control?
	CG15AdultQ26	What is the optimum frequency of clinically monitoring blood glucose control?
	CG15AdultQ68	In newly-diagnosed adults with Type 1 diabetes (excluding those still requiring hospital inpatient treatment) what initial insulin regimens aid glycaemic control?
	CG15AdultQ27	What types of insulin regimen aid optimal diabetic control in adults with stable Type 1 diabetes?
	CG15AdultQ29	In adults with Type 1 diabetes and poorly-controlled blood glucose what insulin regimens can improve diabetic control?
	CG15AdultQ28	What specific advice can be given to adults with Type 1 diabetes for the management and prevention of hypoglycaemia?
	CG15AdultQ30	What method of insulin delivery aids optimal diabetic control in adults with stable Type 1 diabetes?
	CG15AdultQ31	In adults with Type 1 diabetes and poorly-controlled blood glucose what methods of insulin delivery can improve diabetic control?
	CG15AdultQ32	Are there sub-groups of adults with Type 1 diabetes who need a different insulin delivery method to aid optimal diabetic control?
	CG15AdultQ33	Can combination therapy (oral glucose lowering drugs and insulin) improve blood glucose control compared to insulin therapy alone in adults with Type 1 diabetes?
	CG15AdultQ71	What is the most appropriate medical intervention for adults with Type 1 diabetes with severe hypoglycaemia?
	CG15AdultQ35	What is an acceptable level of blood pressure control in adults with Type 1 diabetes?
	CG15AdultQ36	In adults with Type 1 diabetes and hypertension, what is optimum intervention to lower blood pressure?
	CG15AdultQ37	What is the optimum method of surveillance for arterial risk factors in adults with Type 1 diabetes?
	CG15AdultQ38	What are the screening tests for arterial risk factors in adults with Type 1 diabetes?
	CG15AdultQ39	What is an acceptable level of lipid control in adults with Type 1 diabetes?
	CG15AdultQ40	In adults with Type 1 diabetes, what is the optimum method for predicting cardiovascular disease risk?
	CG15AdultQ41	What is the optimum method of management of abnormalities in lipid control in adults with Type 1 diabetes?
	CG15AdultQ42	What is the evidence for the use of antiplatelet agents in the prevention of arterial disease in adults with Type 1 diabetes?
	CG15AdultQ43	In adults with Type 1 diabetes, what is the management of cardiovascular disease?
	CG15AdultQ44	What is the optimum method for surveillance for diabetic eye damage in adults with Type 1 diabetes?
	CG15AdultQ45	What screening tests should be used for diabetic eye damage in adults with Type 1 diabetes?
	CG15AdultQ46	What non-laser, non-surgical means can be used to prevent the development of diabetic eye disease?
	CG15AdultQ47	What non-laser, non-surgical means can be used to slow the progression of diabetic eye disease?
	CG15AdultQ48	When should an adult with Type 1 diabetes and diabetic eye damage be referred to an ophthalmologist?
	CG15AdultQ49	In adults with Type 1 diabetes what is the optimum method of surveillance for the detection of emerging diabetic kidney disease?
	CG15AdultQ50	In adults with Type 1 diabetes what are the screening tests for emerging diabetic kidney disease?
	CG15AdultQ51	What is the appropriate management of early diabetic kidney disease in adults with Type 1 diabetes?
	CG15AdultQ52	When should adults with early symptoms of diabetic kidney disease be referred to a renal specialist?
	CG15AdultQ53	In adults with Type 1 diabetes, what are the optimum methods for surveillance for diabetic foot problems?
	CG15AdultQ54	In adults with Type 1 diabetes, what are the optimum screening tests for diabetic foot problems?
	CG15AdultQ55	What are the optimum methods of managing diabetic foot problems in adults with Type 1 diabetes?
	CG15AdultQ56	In adults with Type 1 diabetes, what is the optimum treatment of foot ulceration and related infection?
	CG15AdultQ57	In adults with Type 1 diabetes, what is the optimum management of painful neuropathy?
	CG15AdultQ58	In adults with Type 1 diabetes, what are the symptoms suggestive of a diagnosis of autonomic neuropathy?
	CG15AdultQ59	What is the optimum method of managing autonomic neuropathy in adults with Type 1 diabetes?
	CG15AdultQ60	In adults with Type 1 diabetes, what are the symptoms suggestive of a diagnosis of gastroparesis?
	CG15AdultQ61	What is the optimum method for surveillance for sexual dysfunction in adults with Type 1 diabetes?
	CG15AdultQ62	What are the optimum methods of management for sexual dysfunction in adults with Type 1 diabetes?
	CG15AdultQ16	How are adults with Type 1 diabetes affected by anxiety and depression?
	CG15AdultQ17	How best is such anxiety and depression diagnosed and managed in adults with Type 1 diabetes?
	CG15AdultQ18	What is the best means of detecting eating disorders in adults with Type 1 diabetes?
	CG15AdultQ19	What is the appropriate management of eating disorders in adults with Type 1 diabetes?
	CG15AdultQ24	What is the optimum management of blood glucose and metabolic control in adults with Type 1 diabetes suffering myocardial infarction and cardiovascular accident?
	CG15AdultQ65	What is the recommended initial assessment plan for newly-diagnosed adults with stable Type 1 diabetes?
	CG15AdultQ66	What is the recommended initial content of education to promote understanding of Type 1 diabetes and improve self-management in newly-diagnosed adults with stable Type 1 diabetes?
	CG15AdultQ67	What is the recommended delivery of education to promote understanding of Type 1 diabetes and improve initial self-management of newly-diagnosed adults with stable Type 1 diabetes?
	CG15AdultQ70	What guidance can be given for optimal insulin delivery during severe concurrent illness?
	CG15AdultQ72	In people with diabetic ketoacidosis what emergency care can reduce morbidity and mortality?
	CG15AdultQ73	What is the most appropriate surveillance and screening for concurrent autoimmune diseases in adults with Type 1 diabetes?
	CG15AdultQ74	What are the optimal insulin regimes during surgical procedures?
	CG10Q1	Care of the diabetic foot without complications
	CG10Q2	Care of the foot at raised risk of complications
	CG10Q3	Care of the ulcerated foot
	CG10Q4	Charcot osteoarthropathy
	PH38Q1	What is the evidence for the effectiveness and cost-effectiveness of methods to identify adults with pre-diabetes, especially the evidence for how to increase identification and the uptake of risk assessment in high-risk groups?
	PH38Q2	What are the most effective and cost-effective methods � lifestyle, pharmacological and surgical � of preventing or delaying type 2 diabetes in adults with pre-diabetes?
	PH38Q3	What is the review level evidence for specific components (or combinations of components) of intervention programme / strategies which are most effective in preventing or delaying progression to type 2 diabetes in adults with pre-diabetes?
	PH38Q4	What is the review and primary level evidence for the most effective methods of preventing or delaying progression to type 2 diabetes in adults with pre-diabetes when intensive interventions assessed in RCTs are adapted to real world settings?
	PH38Q5	What is the evidence identifying views, barriers and facilitators that may affect the implementation and effectiveness of strategies and tools designed to assess the risk of progression to type 2 diabetes in diagnosed and undiagnosed populations
	PH38Q6	What is the evidence in terms of views, barriers and facilitators to the implementation of preventive interventions (e.g. lifestyle)?
	PH38Q7	What is the evidence in terms of views, barriers and facilitators to lifestyle behaviour change, especially in high-risk individuals?
	CG66Q1	Are patient education models effective for people with Type 2 diabetes?
	CG66Q2	Which forms of dietary advice are effective treatments for people with Type 2 diabetes?
	CG66Q3	In people with Type 2 diabetes, what should be the target value for HbA1c?
	CG66Q4	Is metformin as monotherapy or in combination with oral antidiabetic drugs effective in the control of compared to other oral antidiabetic drugs regimens or placebo?
	CG66Q5	Are the insulin secretagogues (sulphonylureas and nateglinide and repaglinide) as monotherapy or in combination with oral antidiabetic drugs effective in the control of blood glucose in people with Type 2
	CG66Q6	Are the glitazones (pioglitazone and rosiglitazone) effective in the control of blood glucose in people with Type 2 diabetes either alone or in combination compared to other antidiabetic treatment regimens?
	CG66Q7	Are the alphaglucosidases inhibitors (acarbose or miglitol) as monotherapy or in combination with oral antidiabetic drugs effective in the control of blood glucose in people with Type 2 diabetes compared to other oral antidiabetic drugs regimens or placebo?
	CG66Q8	Is self-monitoring effective for blood glucose control in patients with Type 2 diabetes?
	CG66Q9	In people with Type 2 diabetes (with and without nephropathy), what should be the target value for blood pressure?
	CG66Q10	Are ACE inhibitors (alone or in combination) effective in the lowering of blood pressure and/or reduction of cardiovascular disease compared with other treatments in people with Type 2 diabetes?
	CG66Q11	Are angiotensin II receptor antagonists (alone or in combination) effective in the lowering of blood pressure and/or reduction of cardiovascular disease compared with other treatments in people with Type 2 diabetes?
	CG66Q12	Are beta blockers (alone or in combination) effective in the lowering of blood pressure and/or reduction of cardiovascular disease compared with other treatments in people with Type 2 diabetes?
	CG66Q13	Are dihydropyridine and non-dihydropyridine calcium channel blockers (alone or in combination) effective in the lowering of blood pressure and/or reduction of cardiovascular disease compared with other treatments in people with Type 2 diabetes?
	CG66Q14	Are thiazide and loop diuretics (alone or incombination) effective in the lowering of blood pressure and/or reduction of cardiovascular disease compared with other treatments in people withType 2 diabetes?
	CG66Q15	In people with Type 2 diabetes, what should be the target value for lipid levels?
	CG66Q16	Are statins effective in improving lipid profiles and other outcomes compared to other treatments or placebo in people with Type 2 diabetes?
	CG66Q17	Are fibrates effective in improving lipid profiles and other outcomes compared to other treatments or placebo in people with Type 2 diabetes?
	CG66Q18	Are nicotinic acid derivatives effective in improving lipid profiles and other outcomes compared to other treatments or placebos in people with Type 2 diabetes
	CG66Q19	Are omega 3s (fish oils) effective in improving lipid profiles and other outcomes compared to other treatments or placebo in people with Type 2 diabetes
	CG66Q20	Which arterial risk tables, equations or engines for calculation of arterial risk are most predictive of arterial disease in people with Type 2 diabetes?
	CG66Q21	Does aspirin prevent vascular disease in people with Type 2 diabetes?
	CG66Q22	Does clopidogrel prevent vascular disease in people with Type 2 diabetes compared to aspirin or in combination with aspirin?
	CG66Q23	Which tests should be used in the diagnosis and management of renal disease?
	CG66Q24	Are tricyclic drugs effective for the treatment of painful neuropathy in people with Type 2 diabetes?
	CG66Q25	Is gabapentin effective for the treatment of painful neuropathy in people with Type 2 diabetes?
	CG66Q26	Is pregabalin effective for the treatment of painful neuropathy in people with Type 2 diabetes?
	CG66Q27	Is carbamazepine effective for the treatment of painful neuropathy in people with Type 2 diabetes?
	CG66Q28	In people with Type 2 diabetes, can gastroparesis be effectively treated with a prokinetic drug (metoclopramide or domperidone)?
	CG66Q29	Are PDE5 inhibitors effective for the treatment of erectile dysfunction in people with Type 2 diabetes?
	CG73Q1	What is the accuracy of equations to estimate GFR as a measurement of kidney function?
	CG73Q2	In adults with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it?
	CG73Q3	What is the sensitivity and specificity of reagent strips for detecting protein and blood in urine?
	CG73Q4	What are the benefits in terms of accuracy and cost in measuring albumin:creatinine ratio versus protein:creatinine ratio to quantify proteinuria in adults with CKD?
	CG73Q5	For people with suspected CKD, what is the effect of proteinuria at any given eGFR on adverse outcomes?
	CG73Q6	In adults, who should be tested for CKD?
	CG73Q7	For people with CKD, does the presence of diabetes have an effect on adverse outcomes at any given category of eGFR and ACR?
	CG73Q8	In people with CKD, what constitutes a clinically significant decline in eGFR?
	CG73Q9	What factors are associated with progression of CKD: ( a) cardiovascular disease; ( b) acute kidney injury; ( c) obesity; ( d) smoking; ( e) urinary tract obstruction; ( f) ethnicity; ( g) chronic use of NSAIDs?
	CG73Q10	When should calcium, phosphate and parathyroid parameters be measured and at what frequency should they be repeated?
	CG73Q11	What are the risks and benefits of bisphosphonates for preventing osteoporosis in adults with CKD?
	TA288Q1	How innovative is the technology in its potential to make a significant and substantial impact on health-related benefits?
	TA288Q2	What is the position of the treatment in the pathway of care for the condition?
	TA288Q3	Adverse reactions
	TA288Q4	Relevance to general clinical practice in the NHS
	TA288Q5	Uncertainties generated by the evidnece
	TA288Q6	Are there any clinically relevant subgroups for which there is evidence of differential effectiveness?
	TA288Q7	Estimate of the size of the clinical effectiveness including strength of supporting evidence
	TA288Q8	Uncertainties around and plausibility of assumptions and inputs in the economic model
	TA288Q9	Uncertainties around and plausibility of assumptions and inputs in the economic model
	TA288Q10	Have any potential significant and substantial health-related benefits been identified that were not included in the economic model, and how have they been considered?
	TA288Q11	Are there specific groups of people for whom the technology is particularly cost effective?
	TA288Q12	What are the key drivers of cost effectiveness?
	TA288Q13	What are the key drivers of cost effectiveness?
	TA288Q14	Equalities considerations and social value judgements
	CG87Q1	What is the additional effect of adding a DPP-4 inhibitor to dual therapy compared with placebo?
	CG87Q2	What is the effect of using a DPP-4 inhibitor in combination with metformin when compared with a sulfonylurea added to metformin?
	CG87Q3	What is the effect of using a DPP-4 inhibitor in combination with a sulfonylurea when compared with a thiazolidinedione in combination with a sulfonylurea?
	CG87Q4	What is the effect of using a DPP-4 inhibitor in combination with a thiazolidinedione when compared with a sulfonylurea in combination with a thiazolidinedione?
	CG87Q5	What is the effect of using a DPP-4 inhibitor in combination with metformin when compared with a thiazolidinedione in combination with metformin?
	CG87Q6	What is the effect of adding a DPP-4 inhibitor to dual oral therapy when compared with adding insulin to dual oral therapy?
	CG87Q7	What is the effect of adding a DPP-4 inhibitor to dual oral therapy compared with adding a thiazolidinedione to dual oral therapy?
	CG87Q8	What is the effect of adding a DPP-4 inhibitor to triple oral therapy when compared with insulin plus metformin?
	CG87Q9	What is the additional effect of adding pioglitazone to an insulin?
	CG87Q10	How safe are rosiglitazone and pioglitazone, and do their safety profiles differ?
	CG87Q11	What is the additional effect of adding a GLP-1 mimetic (exenatide) to dual therapy when compared with placebo?27
	CG87Q12	What is the additional effect of adding a GLP-1 mimetic (exenatide) to metformin when compared with placebo
	CG87Q13	What is the additional effect of adding a GLP-1 mimetic (exenatide) to a thiazolidinedione and a sulfonylurea compared with placebo?33
	CG87Q14	What is the effect of adding a GLP-1 mimetic (exenatide) versus insulin to dual therapy (metformin and a sulfonylurea)?
	CG87Q15	What is the additional effect of adding a GLP-1 mimetic (exenatide) versus thiazolidinedione to dual therapy (metformin and a sulfonylurea)?
	CG87Q16	What is the effect of replacing insulin with a GLP-1 mimetic (exenatide)?
	CG87Q17	Does the effectiveness differ between NPH insulin and a long-acting insulin analogue (insulin glargine, insulin detemir) when a basal insulin is indicated?
	CG87Q18	What is the effect of using insulin glargine compared with insulin detemir?
	CG173Q1	What is the clinical effectiveness of different pharmacological treatments as monotherapy compared with each other or placebo for the management of neuropathic pain in adults, outside of specialist pain management services?
	CG173Q2	What is the clinical effectiveness of different pharmacological treatments as combination therapy compared with other combination therapies, monotherapy or placebo for the management of neuropathic pain in adults, outside of specialist pain management services?
	IPG257Q1	What is the efficacy and safety of allogeneic pancreatic islet cell transp lantation for type 1 diabetes mellitus
	TA71Q1	In the setting of Coronary Artery Disease (CAD), to assess the clinical and cost effectiveness of stents and drug-eluting stents for the prevention of restenosis, compared with Percutaneous Transluminal Coronary Angioplasty (PTCA) and Coronary Artery Bypass Graft (CABG)
	TA152Q1	Assess the clinical and cost effectiveness of drug-eluting stents for the prevention of restenosis following PCI. Drug-eluting stents (DES) will be compared with non drug-eluting stents and a comparison between DES designs will be presented if data allow.
	{
	"name": "Questions",
	"state": "active",
	"created": "2014-07-02T14:07:20.742Z",
	"sources": [
	{
	"web": "https://raw.githubusercontent.com/ryansroberts/RDFProvider/master/Source%20Content/Guideline&Evidence/Questions.csv"
	}
	],
	"profiles": {
	"dataexplorer": "0.9"
	},
	"scripts": [
	{
	"id": "main.js",
	"path": "main.js"
	}
	],
	"views": [
	{
	"id": "grid",
	"label": "Grid",
	"type": "SlickGrid",
	"state": {
	"gridOptions": {
	"editable": true,
	"enabledAddRow": true,
	"enabledDelRow": true,
	"enableReOrderRow": true,
	"autoEdit": false,
	"enableCellNavigation": true
	}
	},
	"queryState": {
	"size": 155,
	"from": 0,
	"q": "",
	"facets": {},
	"filters": []
	}
	},
	{
	"id": "graph",
	"label": "Graph",
	"type": "Graph",
	"queryState": {
	"size": 155,
	"from": 0,
	"q": "",
	"facets": {},
	"filters": []
	}
	},
	{
	"id": "map",
	"label": "Map",
	"type": "Map",
	"queryState": {
	"size": 155,
	"from": 0,
	"q": "",
	"facets": {},
	"filters": []
	}
	}
	],
	"id": "dataexplorer-398030",
	"resources": [
	{
	"backend": "csv",
	"id": "Questions",
	"path": "current.csv",
	"schema": {
	"fields": [
	{
	"id": "Question GUID",
	"label": "Question GUID",
	"type": "string",
	"format": null,
	"is_derived": false
	},
	{
	"id": "Question",
	"label": "Question",
	"type": "string",
	"format": null,
	"is_derived": false
	}
	]
	}
	},
	{
	"backend": "csv",
	"id": "Questions-original",
	"path": "original.csv",
	"schema": {
	"fields": [
	{
	"id": "Question GUID",
	"label": "Question GUID",
	"type": "string",
	"format": null,
	"is_derived": false
	},
	{
	"id": "Question",
	"label": "Question",
	"type": "string",
	"format": null,
	"is_derived": false
	}
	]
	}
	}
	]
	}
	loadDataset("current", function (error, dataset) {
	// error will be null unless there is an error
	// dataset is a Recline memory store (http://reclinejs.com//docs/src/backend.memory.html).
	console.log(dataset);
	});